Several clinical studies have been conducted to evaluate the safety and efficacy of nilotinib in pediatric patients. These studies generally focus on children with Philadelphia chromosome-positive (Ph+) CML who are resistant or intolerant to other TKIs. The results have been promising, showing that nilotinib can be effective in achieving molecular and cytogenetic responses.
